Event
Pre-ESMO 2023 Symposium | Accelerating the Impact of the Cancer Mission Five-Fold: Where Europe Should Invest to Improve Cancer Outcomes in 10 Years Instead of 50
calendar

October 20, 2023

Calendar
clock

(GMT+02:00)

map point

Hotel Silken Puerta Madrid, Juan Rizi Street, 5. 28027, Madrid

Madrid, Spain

View map
Register

View all IQVIA events

Background: Medical oncologists focused on advancing research and treatment options for patients recognize the importance of balancing investment in innovative therapeutics and providing patients access to these with the need to ensure the sustainability of health systems. The Horizon Europe Mission on Cancer and Europe’s Beating Cancer Plan as well as the European Pharmaceutical Strategy are all intended to bring improved outcomes to patients but often with timelines that stretch decades into the future. At the same time, investment levels are constrained by macroeconomic factors, and policymakers must make tough decisions as to where to invest to achieve maximum societal returns.

This symposium will bring together a multi-stakeholder panel to propose ways to accelerate the impact of cost-effective efforts to improve cancer outcomes five-fold – reducing what might take 50 years to only 10 years. It aligns with the aims of the ESMO Congress in Madrid – Good Science, Better Medicine, Best Practice.

Register to attend in-person or virtually.

Format: The symposium will begin with a short 15-minute presentation by the IQVIA Institute to set the stage and provide an evidence base that can inform the subsequent discussion. Panelists will be invited to share their perspectives and respond to questions. We expect an interactive, engaging dialogue.

Potential areas of discussion:

Diagnostics for the precision medicine era

What bottlenecks to optimal care exist in the diagnostics and care delivery area and how much impact could be achieved by reducing or removing these barriers within a decade?

What stops every European patient from getting a modern diagnostic test?

What is the cost of "not testing"?

Where are there low-hanging fruit policy makers should prioritize for improvement and investment that can provide rapid and broad improvement to patient care?

Driving improvements in surgery and radiotherapy What potential do these modalities have to improve cancer care?

Are we making the right level of investment in public R&D efforts relative to their potential?

How do we better champion the development and implementation of innovative surgical and radiotherapy approaches?

How can we more quickly disseminate emerging best practice?

Conducting pragmatic trials to accelerate repurposing and label expansion

Where are the opportunities to bring existing therapies more quickly to patients?

How might pragmatic clinical trials be designed to accelerate evidence development and what magnitude of benefit can be achieved?

What regulatory changes or flexibility might be needed to accommodate non-traditional trial approaches?

What lessons have already been learned about pragmatic trials that can applied more broadly?

Contact Us